(Stroke. 1995;26:2260-2266.)
© 1995 American Heart Association, Inc.
Articles |
Safety of Hypertensive Hypervolemic Therapy With Phenylephrine in the Treatment of Delayed Ischemic Deficits After Subarachnoid Hemorrhage
From the Departments of Neurology (J.A.M., M.N.D.) and Neurosurgery (R.G.D., M.N.D.), Neurology/Neurosurgery Intensive Care Unit, Washington University School of Medicine, St Louis, Mo.
Correspondence to Michael N. Diringer, MD, Washington University School of Medicine, Campus Box 8111, 660 S Euclid Ave, St Louis, MO 63110-1093. E-mail mnd9252@bjcmail.carenet.org.
Background and Purpose Hypertensive hypervolemic therapy has been shown to reverse delayed ischemic deficits after aneurysmal subarachnoid hemorrhage. Concern has been raised about systemic complications of therapy, including pulmonary edema and myocardial ischemia, especially when high doses of vasopressors are used. Patients in whom delayed ischemic deficits were treated with hypervolemia and phenylephrine were prospectively evaluated for signs of systemic toxicity.
Methods Twenty-four consecutive patients treated with hypertensive hypervolemic therapy after aneurysmal subarachnoid hemorrhage were studied. Sixty-seven percent had underlying cardiac disease, vascular disease, or hypertension. No patient was excluded because of age or preexisting cardiac disease. Patients were closely monitored for signs of congestive heart failure (physical examination, chest x-ray films, arterial blood gases, cardiac index, pulmonary artery wedge pressure, and oxygen requirement). Indicators of cardiac ischemia and other extracerebral toxicity that were monitored included cardiac enzymes, electrocardiograms, serum creatinine, electrolyte and lactic acid levels, gastrointestinal motility, and urine output.
Results Volume expansion and phenylephrine infusion produced an increase in several hemodynamic parameters including pulmonary artery wedge pressure, which rose 28% (13±3.6 to 16±1.9 mm Hg), mean arterial blood pressure, which rose 25% (99±12.5 to 123±11.4 mm Hg), and systemic vascular resistance, which rose 46% (1234±294 to 1739±315 dyne · s-1 · cm-5); however, there was no change in cardiac index (3.9±0.9 to 4.0±0.6 L · min-1 · m-2). There were no clinically significant episodes of pulmonary edema requiring a change in vasopressor therapy and no myocardial infarctions. Phenylephrine was stopped in only one patient (incidence, 4%; 95% confidence interval, 0% to 12%), who developed an exacerbation of his preexisting bradycardia. There was no evidence of noncardiac organ system toxicity. Eighty-eight percent of the patients exhibited neurological improvement.
Conclusions Hypertensive hypervolemic therapy with the use of high-dose phenylephrine can be administered with acceptable systemic toxicity, even in patients with previous cardiac disease, provided that close monitoring is performed. To minimize risk, aggressive treatment should probably be reserved for patients with signs of delayed ischemia rather than administered prophylactically.
Key Words: heart disease • hypertension • lung • subarachnoid hemorrhage • vasospasm
This article has been cited by other articles:
 |
|
 |
|
  R. Dhar, A. R. Zazulia, T. O. Videen, G. J. Zipfel, C. P. Derdeyn, and M. N. Diringer Red Blood Cell Transfusion Increases Cerebral Oxygen Delivery in Anemic Patients With Subarachnoid Hemorrhage Stroke, September 1, 2009; 40(9): 3039 - 3044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tung, A. Kopelnik, N. Banki, K. Ong, N. Ko, M. T. Lawton, D. Gress, B. Drew, E. Foster, W. Parmley, et al. Predictors of Neurocardiogenic Injury After Subarachnoid Hemorrhage Stroke, February 1, 2004; 35(2): 548 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Aiyagari, D. T. Cross III, E. Deibert, R. G. Dacey Jr, and M. N. Diringer Safety of Hemodynamic Augmentation in Patients Treated With Guglielmi Detachable Coils After Acute Aneurysmal Subarachnoid Hemorrhage Stroke, September 1, 2001; 32(9): 1994 - 1997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rordorf, W. J. Koroshetz, M. A. Ezzeddine, A. Z. Segal, and F. S. Buonanno A pilot study of drug-induced hypertension for treatment of acute stroke Neurology, May 8, 2001; 56(9): 1210 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mayer, J. Lin, S. Homma, R. A. Solomon, L. Lennihan, D. Sherman, M. E. Fink, A. Beckford, and L. M. Klebanoff Myocardial Injury and Left Ventricular Performance After Subarachnoid Hemorrhage Stroke, April 1, 1999; 30(4): 780 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H Vermeij, D. Hasan, H. W. C. Bijvoet, and C. J. J. Avezaat Impact of Medical Treatment on the Outcome of Patients After Aneurysmal Subarachnoid Hemorrhage Stroke, May 1, 1998; 29(5): 924 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rordorf, S. C. Cramer, J. T. Efird, L. H. Schwamm, F. Buonanno, and W. J. Koroshetz Pharmacological Elevation of Blood Pressure in Acute Stroke : Clinical Effects and Safety Stroke, November 1, 1997; 28(11): 2133 - 2138. [Abstract] [Full Text]
|
|
|
|
|
|
S. Joshi, W. L. Young, J. Pile-Spellman, P. Fogarty-Mack, R. R. Sciacca, L. Hacein-Bey, H. Duong, Y. Vulliemoz, N. Ostapkovich, and T. Jackson Intra-arterial Nitrovasodilators Do Not Increase Cerebral Blood Flow in Angiographically Normal Territories of Arteriovenous Malformation Patients Stroke, June 1, 1997; 28(6): 1115 - 1122. [Abstract] [Full Text]
|
|